Oncology Deal-Making The Daiichi Way
$13bn Deal Value In 18 Months
Daiichi Sankyo’s relatively young strategic pivot into oncology is paying major dividends, with two huge global deals with AstraZeneca now in the bag within 18 months. Scrip takes a closer look with the help of insights from the Japanese firm’s global oncology R&D head.
You may also be interested in...
Also, Osmotica licenses rights to ophthalmic drug in Japan, China and the EMEA nations to Santen; Lilly and Chi-Med revise their partnership around colorectal cancer drug Elunate.
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.
Independent drug cost watchdog updates its twin pricing estimates for Gilead's drug - but dexamethasone could tip the balance again.